翻译尚未完成，当前显示原文。
Key PointsImmunityBio's quarterly product sales rose 53% from a year earlier, but they slipped from the prior quarter and missed Wall Street's estimate.
我们公开展示核心要点。创建免费账户后可继续阅读全文、保存、讨论，并结合市场和 OSINT 背景分析。
Veytics Intelligence
Why ImmunityBio Stock Dropped 15% After Earnings Despite 53% Sales Growth. Is IBRX Now a Buy?
